Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:appointed_by |
inhalation
|
| gptkbp:approves |
gptkb:2017
|
| gptkbp:class |
gptkb:physicist
long-acting beta agonist long-acting muscarinic antagonist |
| gptkbp:clinical_trial |
Phase III
preventive treatment maintenance treatment |
| gptkbp:contains |
fluticasone furoate
umeclidinium vilanterol |
| gptkbp:contraindication |
hypersensitivity to ingredients
severe asthma exacerbation |
| gptkbp:dosage_form |
dry powder inhaler
|
| gptkbp:duration |
once daily
|
| gptkbp:effective_date |
FDA approved
|
| gptkbp:formulation |
powder for inhalation
|
| https://www.w3.org/2000/01/rdf-schema#label |
Trelegy Ellipta
|
| gptkbp:indication |
gptkb:asthma
|
| gptkbp:ingredients |
fluticasone furoate
umeclidinium vilanterol |
| gptkbp:interacts_with |
corticosteroids
beta-blockers anticholinergics |
| gptkbp:is_monitored_by |
adverse effects
lung function symptoms of COPD |
| gptkbp:is_used_for |
chronic obstructive pulmonary disease
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:marketed_as |
Trelegy
|
| gptkbp:packaging |
blister pack
|
| gptkbp:population |
adults
children over 12 |
| gptkbp:requires |
prescription only
|
| gptkbp:safety_features |
not for use in children under 12
not for acute use |
| gptkbp:shelf_life |
check packaging
|
| gptkbp:side_effect |
gptkb:healthcare_organization
dizziness headache nausea cough dry mouth nervousness increased heart rate nasopharyngitis thrush |
| gptkbp:storage |
store at room temperature
|
| gptkbp:type_of_care |
important for efficacy
|